Jevtana: new option for metastatic prostate cancer

Jevtana (cabazitaxel) is a novel taxane and is licensed for the treatment of hormone refractory metastatic prostate cancer in patients who have been previously treated with docetaxel.

Jevtana increases median overall survival compared with mitoxantrone
Jevtana increases median overall survival compared with mitoxantrone


Cabazitaxel is a novel taxane antineoplastic agent, which stabilises the microtubule network by binding to tubulin, thereby preventing the breakdown required for cancer cell division.1


The open-label, randomised phase 3 TROPIC study (n=755) compared the efficacy and safety of cabazitaxel against mitoxantrone, both in combination with either prednisone or prednisolone, in patients with hormone-refractory metastatic prostate cancer who had previously received a docetaxel-containing regimen. The primary endpoint used was overall survival.2

The data were analysed on an intention to treat basis. At the cut-off for final analysis, median overall survival was longer in the cabazitaxel group (15.1 months) than in the mitoxantrone group (12.7 months; p<0.0001), indicating that cabazitaxel provides a 30% reduction in the risk of death compared with mitoxantrone.2

In addition, median progression-free survival was approximately doubled in patients treated with cabazitaxel (2.8 months) compared with those who received mitoxantrone (1.4 months; p<0.0001).2

There was no significant difference between treatment arms with regard to pain progression or pain response.2


  1. Jevtana Summary of Product Characteristics, March 2011.
  2. de Bono JS et al. Lancet 2010; 376: 1147–54.

View Jevtana drug record

Further Information: Sanofi–aventis

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

A woman wearing a white vest as a blue-gloved hand of a healthcare professional are seen injecting a vaccine.

'Nocebo' effect may cause two-thirds of COVID-19 vaccine reactions, study suggests

Two-thirds of adverse reactions reported with the COVID-19...

An elderly woman with one arm in a plaster cast sits resting both hands on her walker

Doctors urge NICE to reverse decision on new osteoporosis drug

More than NHS 100 clinicians have called on NICE to...

Image of both strengths of Seffalair Spiromax inhaler side by side.

New salmeterol/fluticasone dry powder inhaler for asthma

Seffalair Spiromax is the sixth dry powder salmeterol/fluticasone...